IP Library › Granted Patent US 11,708,331
Granted Patent B2
US 11,708,331 · App. 16/768,178 · Granted Jul 25, 2023

Processes for making modulators of cystic fibrosis transmembrane conductance regulator

Inventors: Berenice Lemercier Lewandowski (Braintree, MA); Robert Lewis (Waltham, MA); Adam Looker (Newtonville, MA); Adam Morgan (Ashland, MA); Stefanie Roeper (Medford, MA); Michael Ryan (Roxbury, MA); Juan Gabriel Solsona Rocabert (Barcelona, ES); Nathan Wilde (Poway, CA)
Assignee: Vertex Pharmaceuticals Incorporated
C07D215/56C07B59/002C07C39/06C07C69/96C07C205/43C07C219/34C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,708,331
App. No.
16/768,178
Granted
Jul 25, 2023
Kind
B2
Abstract

The disclosure provides processes for synthesizing compounds for use as CFTR modulators.

Claims (25)

1. A compound selected from:

and salts thereof.

2. A process for the preparation of compound 1:

comprising:

a) converting compound 12:

into compound 11A:

wherein the conversion of compound 12 into compound 11A is performed in the presence of KNO 3 and/or NaNO 3 , AlCl 3 , and optionally one or more of trimethylsilyl chloride and TiCl 4 ;

b) converting compound 11A into compound 4:

c) reacting compound 3:

with compound 4 to produce compound 5:

and

d) converting compound 5 into compound 1;

wherein the methyl (Me) of the —OCO 2 Me of each of compounds 4, 5, 11A, and 12 is optionally replaced by a group selected from aliphatic, heteroaliphatic, heterocyclic, haloaliphatic, aryl, and heteroaryl.

3. A process for the preparation of compound 11A:

comprising converting compound 12:

into compound 11A;

wherein the conversion of compound 12 into compound 11A is performed in the presence of KNO 3 and/or NaNO 3 , AlCl 3 , and optionally one or more of trimethylsilyl chloride and TiCl 4 ; and

wherein the methyl (Me) of the —OCO 2 Me of each of compounds 11A and 12 is optionally replaced by a group selected from aliphatic, heteroaliphatic, heterocyclic, haloaliphatic, aryl, and heteroaryl.

4. The process of claim 2 or 3 , wherein the conversion of compound 12 into compound 11A is performed in the presence of KNO 3 , AlCl 3 , and trimethylsilyl chloride.

5. The process of claim 2 or 3 , wherein the conversion of compound 12 into compound 11A is performed in the presence of KNO 3 and AlCl 3 .

6. The process of claim 2 or 3 , wherein the conversion of compound 12 into compound 11A is performed in the presence of NaNO 3 and AlCl 3 .

7. The process of claim 2 or 3 , wherein the conversion of compound 12 into compound 11A is performed in the presence of a solvent.

8. The process of claim 7 , wherein the solvent is CH 2 Cl 2 .

9. The process of claim 2 or 3 , wherein compound 12 is produced by converting compound 13:

into compound 12.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2020
From: LOOKER, ADAM; WILDE, NATHAN; RYAN, MICHAEL; LEWANDOWSKI, BERENICE LEMERCIER; ROEPER, STEFANIE
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 053761/0229 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2020
From: LEWIS, ROBERT
To: CONCERT PHARMACEUTICALS INC.
Reel/Frame 053761/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2020
From: MORGAN, ADAM
To: CONCERT PHARMACEUTICALS INC.
Reel/Frame 053761/0272 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2020
From: ROCABERT, JUAN GABRIEL SOLSONA
To: ESTEVE QUIMICA, S.A.
Reel/Frame 053761/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2020
From: CONCERT PHARMACEUTICALS INC.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 053761/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2020
From: ESTEVE QUIMICA, S.A.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 053762/0098 →
Priority Claims (1)
EP 17382829 · Dec 1, 2017 · regional
Continuity (1)
Related Publication 20200290972A1 · Sep 17, 2020
Cited By (4)
US 12,269,831 US 12,324,802 US 12,421,251 US 12,612,416